Elizabeth S. Weiswasser

Intellectual Property

Gregory Silbert, Elizabeth S. Weiswasser, Todd Larson, Randi W. Singer | Weil, Gotshal & Manges LLP

Weiswasser: I’m going to cover a few of the patent cases that are before the Court this term. This term, the Court is going to be testing certain core questions of what can be patented and what is needed to show patent infringement, and also scrutinizing the circumstances in which fee-...

Healthcare

Patrick J. O'Toole, Jr., Elizabeth S. Weiswasser, Matthew L. Knowles, Bryana T. McGillycuddy | Weil, Gotshal & Manges LLP

Introduction A controversy over what the Supreme Court has now defined as “reverse payment settlement agreements” has been brewing for years. A reverse payment settlement agreement is a settlement agreement resolving patent infringement litigation brought by an innovator against a...

Biotechnology | Life Sciences

Elizabeth S. Weiswasser | Weil, Gotshal & Manges LLP

Editor: Please tell us about your professional background. Weiswasser: My scientific training is in biochemistry and molecular biology, and I focus my patent litigation and counseling practice on the biotech and pharmaceutical industries. Over the years I have worked extensively with...

Elizabeth S. Weiswasser, Vernon M. Winters, Steven D. Glazer | Weil, Gotshal & Manges LLP

Our article in the August 2004 issue of The Metropolitan Corporate Counsel discussed the Federal Circuit's internal debate as to whether section 112 of the Patent Act contains a separate written description requirement. We concluded by noting that it remains to be seen whether the Federal Circuit...

Elizabeth S. Weiswasser, Vernon M. Winters, Steven D. Glazer | Weil, Gotshal & Manges LLP

Part I of this article, appearing in the July 2004 issue of The Metropolitan Corporate Counsel, discussed earlier case law's requirements of descriptive information required for patent validity.Federal Circuit Written Description Cases In 2003 Twice in 2003 the Federal Circuit reaffirmed the...